Please login to the form below

Not currently logged in
Email:
Password:

UCB strikes new Middle East and African sales deal for key products

Drops the RX Group to partner with NewBridge Pharmaceuticals

UCB sign

UCB has picked up a new commercial partner for three of its key products in the Middle East and Africa, striking a deal with NewBridge Pharmaceuticals and dropping former partner the Rx Group.

The deal covers the Belgium biopharmaceutical firm's Cimzia (certolizumab pegol) for Crohn's disease and rheumatoid arthritis, Vimpat (lacosamide) for epilepsy and Neupro (rotigotine) for Parkinson's disease and restless legs syndrome.

The three drugs achieved 45 per cent growth in global sales that came to €413m for the first half of this year and UCB has ambitions for the trio of treatments to reach more than 1.5 million patients.

Its head of international major markets Luc Vermeesch said: “Within UCB we are passionate about enabling families with severe diseases to enjoy normal, everyday lives.

“To reach this objective we are thrilled to be working with NewBridge Pharmaceuticals, and rely on their solid experience and strong leadership team in the Middle East and Africa region.”

Through the deal NewBridge will acquire local rights to UCB's three key drugs and will be responsible for managing the local regulatory approval process, future commercialisation, and pharmacovigilance for several Middle East and African countries.

Joe Henein, president and CEO of NewBridge, said: “This transaction represents a major milestone for NewBridge as we execute on our high growth strategy to provide access to innovative therapeutics in our core markets of the Middle East and Africa.

“We strongly believe that Cimzia, Vimpat and Neupro have great potential in our territory and will contribute significantly to the physicians' abilities to treat patients with immunologic and CNS afflictions respectively, thereby improving quality of life for these patients.”

Dubai-based NewBridge Pharmaceuticals is a specialty therapeutics company that focuses on commercialising pharmaceutical, biologic, diagnostic and medical device products across the AfMET markets (Africa, Middle East, Turkey & Caspian regions).

The firm was set up last year to specialise in in-licensing, acquiring, registering and commercialising therapeutics approved by regulators in the US, Europe and Japan.

22nd November 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics